Building: BSB Room: L.141The Macromolecular X-ray and Computing facility is located at L141 of the main campus, 3333 Green Bay Road, North Chicago, IL 60064. It supports structural biology projects that utilize X-ray crystallography and molecular modeling. Core instrumentation for crystallization consists of the robot Mosquito from TPP Labtech, and the Korima UV fluorescence visualization system. In-house diffraction experiments are performed on an R-axis area detector or a Bruker CCD detector, using the high-brilliance Rigaku generator, a rotating copper anode, and Oxford mirrors. Cryogenic cooling is provided by the Rigaku X-stream or the Oxford Cryosystem. Synchrotron diffraction data is collected at APS Argonne National Laboratory near Chicago. Rosalind Franklin University is a member of SER-CAT (www.ser.aps.anl.gov) with regular access to APS beamlines 22ID and 22BM. Computing is based on a 6TB Linux server and several NFS-connected client computers with 3D graphics. Multiple software suites are kept up to date by Structural Biology Grid (www.sbgrid.org). Modeling packages include Molecular Operating Environment (www.chemcomp.com) and SCHRODINGER (www.schrodinger.com).

6780 Ayala Avenue, 9th Floor Makati City, Manila PhilippinesSynchrogenix partners with pharmaceutical and biotech companies to develop submission documents for global regulatory agencies. Since 1986, our core competency at Synchrogenix has been regulatory writing for the pharmaceutical and biotech industry. Focusing on this crucial aspect of the drug development process has allowed us to hone our unique methodology and build a team of regulatory writers who are experts and thought leaders in the field. Rather than vertically specializing in a functional area, as a CRO, CMO, or contract lab might, Synchrogenix horizontally bridges all functional areas within drug development. Our strength is integrating with key stakeholders to create submission documents that are comprehensive, concise, and clear, as well as consistent within and across the entire submission. Synchrogenix breaks through silos, uniting many single elements into one story…your story. Synchrogenix is a leader in the regulatory writing field with a singular focus of authoring and editing regulatory documentation. We know that we are only as good as the documents that we produce. Therefore we are dedicated to the following ideals: Nurturing our writers and editors to increase their knowledge of drug and biological development, and to ensure they are comfortably challenged in their careers. Remaining immersed in global pharmaceutical, biotech, device, and diagnostics regulatory documentation requirements, to understand and anticipate our clients’ needs. Ensuring that we utilize technologies and safety systems that offer the level of sophistication that is vital to our clients. By merging our cross-functional expertise with our writing experience, we deliver documents that not only support clients’ strategic messaging, but also enhance their marketability. We provide many of the benefits of in-house writers—including the experience and perspective of industry insiders—without increased overhead or struggles with fluctuating workloads.

710 AXA Life Center, Sen. Gil Puyat Ave Corner Tindalo St San Antonio Village, Makati City 1200 Metro Manila, PhilippinesAjanta Pharma offers API synthesis, dosage formulation, and manufacturing of pharmaceutical products.

2129 Chino Roces Avenue 3Rd Floor, Kingscourt Bldg. 1 Makati City , Makati , 1200 PhilippinesFounded in 1982, Simian Conservation Breeding & Research Center, Inc is a mature organization in the pharmaceutical products wholesale and manufacturer companies industry located in Makati, Philippines.

9002 Research Drive Filinvest Corporate City Alabang Muntinlupa City, Metro Manila, 1781 PhilippinesThe Research Institute for Tropical Medicine (RITM) had its humble beginnings soon after the culmination of over a decade of negotiations between the governments of the Philippines and Japan for the establishment of a tropical medicine research center. RITM was tasked to plan and implement research programs for infectious and tropical diseases. The original building facilities of RITM, which included a laboratory wing and a 50-bed hospital for patients with infectious diseases requiring tertiary care, were inaugurated on April 23, 1981. In 1984, RITM’s facilities were expanded to include a building for animal research and laboratory animal breeding. Through another grant-in-aid from the Japanese Government, the RITM Center for Training in Tropical Infectious Diseases was established for in-country and third country training activities in 1989. In November 2000, the Biologicals Production Service (BPS) of the Department of Health (DOH) was formally merged with the RITM. The BPS was established as a vaccine laboratory in the country, with the smallpox vaccine as its first product. The vaccine laboratory was later expanded to produce other vaccines as well as anti-sera. The merger of RITM and BPS gave rise to a more comprehensive and logical approach in the control of infectious and/or tropical diseases through research and biologicals production. In 2000, RITM was designated as the National Reference Laboratory (NRL) for dengue, influenza, enteroviruses, measles and other viral exanthems, polio, tuberculosis and other mycobacteria, bacterial enteric diseases, mycology, emerging diseases, malaria and other parasites. It is also the confirmatory testing laboratory of blood donor units for the National Voluntary Blood Services Program; the coordinating center for antimicrobial resistance surveillance; a provider of the National External Quality Assurance for Bacteriology, Parasitology and Mycobacteriology; and a WHO-recognized National Influenza Center. Thirty years after its establishment, RITM has emerged as a center for excellence in health research using the tools available in epidemiology, clinical medicine supported by microbiology, parasitology, public health, virology, immunology, molecular biology, pathology and behavioral/social science. To be relevant to the national health policy and strategy, the research efforts of the Institute have been directed towards the development of new diagnostic techniques, and effective and efficient strategies for the control of infectious and/or tropical diseases. Its research efforts are being disseminated through local and international publications, presented in various scientific meetings and submitted to the health policy-making bodies. VISION A dynamic institution responsive to public health needs through excellence in research, training, control and management of infectious and tropical diseases MISSION Conduct globally competitive research and provide relevant, quality health services to protect Filipinos against infectious, tropical and dermatological diseases